VEGFA and neoplasm: In our exploratory analysis of tumor response, treatment at or below the MTD resulted in a PR rate of 33.3 %, durable SD (≥23 weeks) rate of 22.2 %, and median PFS of approximately 10.9 months in patients who received a median of 1.5 prior anti-VEGF treatments.